DaVita HealthCare Partners Inc. (DVA), the largest provider of dialysis services in the United States, reported mixed financial results for the third quarter of 2024 amid ongoing industry challenges and fluctuations in patient volume.

The company's consolidated revenues for Q3 2024 reached $3.264 billion, exceeding analyst estimates of $3.247 billion. However, the adjusted diluted earnings per share (EPS) of $2.59 fell short of the projected $2.73, impacted by higher patient care costs and operational expenses.

DaVita's U.S. dialysis segment, the primary revenue driver, experienced a slight decline in treatment volume. The company reported 7,350,784 treatments during the quarter, a 0.1% decrease on a per day basis compared to the second quarter of 2024. This drop in patient volume poses a challenge to DaVita's revenue growth and profitability.

Despite the headwinds, DaVita demonstrated strong cash flow generation, with operating cash flow of $810 million and free cash flow of $555 million for the quarter. The company's operating income reached $535 million, representing an operating margin of 16.4%.

DaVita's CEO, Javier Rodriguez, acknowledged the resilience of the company's patients and frontline caregivers, commending their remarkable perseverance in the face of recent severe storms.

"We continue to provide quality care for our patients across the continuum of care, while delivering solid third quarter financial performance," Rodriguez stated.

Looking ahead, DaVita remains focused on its integrated kidney care and risk-based initiatives, which now account for a substantial portion of the company's medical spend. However, sustaining financial performance will require continued efforts to manage patient volume fluctuations and control costs effectively.